While EGFR mutations are rarely observed in primary pancreatic adenocarcinomas, they are well-established oncogenic drivers in lung adenocarcinomas, particularly in Asian populations and non-smokers. This evidence concerns the gene EGFR and pancreatic adenocarcinoma.